- Previous Close
0.1045 - Open
0.1010 - Bid 0.1005 x --
- Ask 0.1010 x --
- Day's Range
0.1010 - 0.1015 - 52 Week Range
0.0820 - 0.4600 - Volume
26,536 - Avg. Volume
80,424 - Market Cap (intraday)
13.851M - Beta (5Y Monthly) 0.19
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2500 - Earnings Date Feb 22, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. The company's oncology pipeline in clinical development includes Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug that binds and blocks androgen receptors; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological conditions, such as breast cancer, head and neck cancer, and prostate cancer; and Nanoimod, a NanoZolid-formulated agatolimod, which is a toll-like receptor 9 (TLR9) agonist. The company was founded in 2003 and is based in Uppsala, Sweden.
www.liddspharma.comRecent News: LIDDS.ST
View MorePerformance Overview: LIDDS.ST
Trailing total returns as of 12/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LIDDS.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LIDDS.ST
View MoreValuation Measures
Market Cap
13.85M
Enterprise Value
2.90M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.01
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-61.89%
Return on Equity (ttm)
-114.25%
Revenue (ttm)
17k
Net Income Avi to Common (ttm)
-25.6M
Diluted EPS (ttm)
-0.2500
Balance Sheet and Cash Flow
Total Cash (mrq)
8.01M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.89M